Leukemia, Myeloid, Acute D015470

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Myeloid » Leukemia, Myeloid, Acute

Description

Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.   MeSH

Subtype Terms (7)

Leukemia, Basophilic, Acute
 

Leukemia, Eosinophilic, Acute
56 drugs (41 approved, 15 experimental)

Leukemia, Erythroblastic, Acute
7 drugs (6 approved, 1 experimental)

Leukemia, Mast-Cell
23 drugs (16 approved, 7 experimental)

Leukemia, Megakaryoblastic, Acute
18 drugs (12 approved, 6 experimental)

Leukemia, Monocytic, Acute
72 drugs (49 approved, 23 experimental)

Leukemia, Promyelocytic, Acute
24 drugs (17 approved, 7 experimental)


Phase 3 Indicated Drugs (99)

Phase 2 Indicated Drugs (294)

8-chloro-adenosine

abatacept (orencia)

acetaminophen (tylenol)

adct-301

agn-195183

alisertib

allogeneic adipose derived mesenchymal stem cell

allogeneic bone marrow

allogeneic natural killer cells

allogeneic transplant donor lymphocytes, depleted of tcr-αβ t cells and b cells; enriched for nk cells and tcrγδ t cells

allopurinol (zyloprim)

alloreactive nk cells

alovudine

alpelisib (Piqray)

alt-803

alvocidib

alx148

amphotericin b (fungizone)

anidulafungin (eraxis)

anti-minor histocompatibility complex (miha) donor t-lymphocytes

apg-2575

apr-246

as-101

as1411

aslan003

asp7517

atezolizumab (tecentriq)

autologous bone marrow

autologous dendritic cells electroporated with wt1 mrna

autologous hematopoietic stem cells

autologous mesenchymal stem cells

autologous natural killer cells

autologous platelets

autologous regulatory t cells

avelumab (bavencio)

axitinib (inlyta)

aza-ven-allo-hsct

azd1775

azd2811

basiliximab (simulect)

beclomethasone (vanceril)

belinostat (beleodaq)

bemcentinib

bendamustine (treanda)

beractant (survanta)

bevacizumab (avastin)

bexarotene (targretin)

bi-2536

bi-811283

bi 836858

binimetinib (mektovi)

bisantrene hydrochloride

bkt-140

blinatumomab (blincyto)

bnt162b2

bone marrow derived mesenchymal stem cells

bp1001

bpx-501

brentuximab vedotin (adcetris)

bryostatin

bst-236

camrelizumab

car.70/il15-transduced cb-nk cells

carboplatin (paraplatin)

carmustine (bicnu)

cb-839

cc-486

cd3,cd19 depleted hematopoietic stem cells

cd3-cd56+ natural killer cells

cd45-depleted allogenic peripheral blood stem cell

cd8+ t cells

cdx-301

cediranib

cenersen

Phase 1 Indicated Drugs (299)


Organization Involved with Phase 3 Indications (182)

Organization Involved with Phase 2 Indications (309)

ADC Therapeutics SARL

Akinion Pharmaceuticals AB

ALFA cooperative Group

Ambit Biosciences

Amgen

AnorMED

Aprea Therapeutics AB

Aptose Biosciences Inc.

argenx

Ariad Pharmaceuticals

Array BioPharma

Ascentage Pharma Group Inc.

Aslan Pharmaceuticals

Assisi Foundation

Associazione Italiana per la Ricerca sul Cancro

Asterias Biotherapeutics

AVEO Pharmaceuticals

AZ Sint-Jan

Bambino Gesù Hospital and Research Institute

Bayer

Baylor University

Beat AML

Belgian Hematological Society

Bellicum Pharmaceuticals

Ben Gurion University

BerGenBio ASA

Bio-Cancer Treatment International Limited

Biodesix Inc.

Bioenvision

BioLineRx, Ltd.

BioMAS Ltd

BioMed Valley Discoveries, Inc

Bio-Path Holdings, Inc.

BioSight Ltd.

Biosuccess Biotech Co., Ltd.

Bristol-Myers Squibb

Brown University

Cancer Insight, LLC

Cantex Pharmaceuticals

Cardiff Oncology

Case Western Reserve University

Celerion

Celldex Therapeutics

Cellerant Therapeutics

Cell Genesys

Cellgenix

Cell Therapy Catapult

Chao Family Comprehensive Cancer Center

Children's Hospital Los Angeles

Children's National Medical Center

Chonbuk National University

Chongqing Medical University

Chongqing Precision Biotech Co., Ltd

Chroma Therapeutics

Chu De Liège

CHU Mont-Godinne

Chung-Ang University

City of Hope National Medical Center

Clear Creek Bio, Inc.

Clinique Charcot

Colorado Blood Cancer Institute

Columbia University

Cookies for Kids' Cancer

CTC Bio, Inc.

CTI BioPharma

Curie Institute

DCPrime BV

Department of Health and Human Services

Department of Health, United Kingdom

Department of Veteran Affairs

DKMS Stiftung Leben Spenden

Doris Duke Charitable Foundation

Dutch Cancer Society

East Carolina University

ECOG-ACRIN Cancer Research Group

Eleos, Inc.

Emory University

ERYtech Pharma

European Commission

Ewha Womans University

Exelixis

F2G Ltd.

Fate Therapeutics

Federal University of Rio Grande do Sul

Fondation ARC

Forma Therapeutics, Inc.

Fortress Biotech

Free University of Brussels

Fresenius

Friedrich Schiller University

Froedtert Memorial Lutheran Hospital

Fujifilm

Gemin X

Genta

Georgetown University

GlaxoSmithKline

Glycostem Therapeutics BV

GOELAMS Cooperative Group

Golden Biotechnology Corp.

Good Samaritan Hospital, Cincinnati

Government of China

Government of Italy

Government of Spain

Groupe Francophone des Myelodysplasies

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

GWT-TUD GmbH

Hanmi Pharmaceutical

Hannover Medical School

Hanyang University

Hebrew University

Hefei University

Hematologics, Inc

Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Hospital La Paz

Hospital San Pedro de Alcantara

Humboldt University

Hybrigenics

I-Mab Biopharma

Immune System Key Ltd

ImmunogenX

INC Research

Incyte

Innate Pharma

Innovative Therapies For Children with Cancer Consortium

Innovent Biologics (Suzhou) Co. Ltd.

Institut Paoli-Calmettes

inVentiv

IQVIA

Istituto Nazionale per lo Studio e la Cura dei Tumori

Jin Yang Pharmaceutical

Julius-Maximilians University

Kartos Therapeutics, Inc.

Karyopharm Therapeutics Inc

Katholieke Universiteit Leuven

Keio University

Kiadis Pharma

Konkuk University

Korea Research Institute of Bioscience and Biotechnology

Kura Oncology, Inc.

Leiden University

Leo W. Jenkins Cancer Center

Luoyang Central Hospital

MaaT Pharma

Marker Therapeutics

Mateon Therapeutics

Mayo Clinic

McGill University

Medac

Medical University of South Carolina

MediGene

MedImmune

Medivation

Memorial Sloan-Kettering Cancer Center

Merck KGaA

Methodist Cancer Center, Houston, Texas

MethylGene Inc.

Miltenyi Biotec, Inc.

Mirati Therapeutics Inc.

Moleculin, LLC

MolMed S.p.A.

Monash University

Monter Cancer Center

Moorgreen Hospital, Southampton

National Institutes of Health (NIH)

Nerviano Medical Sciences

NewLink Genetics Inc

New York Medical College

New York University

NexImmune Inc.

Nohla Therapeutics, Inc.

Nordic MDS Group

North Shore Hospital, New Zealand

Northside Hospital, Inc.

Ohio State University

OHSU Knight Cancer Institute

OncoEthix

Onconova Therapeutics, Inc.

OncoTherapy Science, Inc.

Onxeo

Oregon Health and Science University

Oshadi Drug Administration

OSI Pharmaceuticals

Ospedale Sant' Eugenio

Otsuka

Paris Diderot University

Pavlov First Saint Petersburg State Medical University

Pediatric Brain Tumor Consortium

Pennsylvania State University

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Peter MacCallum Cancer Centre

Pharmacyclics

Plexxikon

Polaris Group

PrECOG, LLC.

Prism Research

Proacta, Incorporated

Pusan National University

Race Oncology Ltd

Rhode Island Hospital

Rocky Mountain Cancer Centers - Denver Midtown

Royal Marsden Hospital NHS Trust

Rush University

S*BIO

Schering-Plough

SCRI Development Innovations

Selvita S.A.

Seoul National University

Servier

SGX Pharmaceuticals

Shanghai institute of Hematology

Shanghai Ruijin Hospital North

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Sheba Medical Center

Sheffield Hallam University

Shenzhen Geno-Immune Medical Institute

Shijiazhuang Pharma Group (CSPC)

Soonchunhyang University

Spectrum Pharmaceuticals

Spedali Civili di Brescia

Spirogen

Sponsor GmbH

State of Texas

St. Baldrick's Foundation

Stemline Therapeutics, Inc.

Sumitomo

Sungkyunkwan University

Sutter Health

Suzhou Yasheng Pharmaceutical Co., Ltd

Swiss Group for Clinical Cancer Research

Symphony Capital

Synimmune GmbH

Syntax for Science

Syros Pharmaceuticals

Takeda

Technical University of Munich

Telios Pharma, Inc.

Temple University

Texas Oncology Cancer Center

The Cleveland Clinic

The EMMES Corporation

The First People's Hospital of Yunan Province

The Foundation Institute San Raffaele G. Giglio of Cefalù

The Korean Society of Hematology

The Korean Society of Pediatric Hematology Oncology

Theradex

The University of Texas, Dallas

Thomas Jefferson University

Tokyo Metropolitan Komagome Hospital

Tolero Pharmaceuticals

Tufts University

Universidad Autonoma de Madrid

Universita' Cattolica del Sacro Cuore

Universitair Ziekenhuis Gent

Université catholique de Louvain

University Hospital of Mont-Godinne

University of Alabama, Birmingham

University of Arizona

University of Bergen

University of Bern

University of Bologna

University of Bonn

University of California, Davis

University of California, Irvine

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Campinas

University of Cincinnati

University of Colorado, Denver

University of Duesseldorf

University of Geneva

University of Iowa

University of Jena

University of Kentucky

University of Lausanne

University of Liege

University of Lille

University of Maryland

University of Medicine and Dentistry of New Jersey

University of Melbourne

University of Miami

University of Michigan

University of Minnesota

University of Montreal

University of Nebraska

University of New Mexico

University of North Carolina at Chapel Hill

University of Pittsburgh

University of Rochester

University of Rostock

University of Seville

University of Southern California

University of South Florida

University of Toronto

University of Tuebingen

University of Wisconsin

Uppsala University

Vanderbilt University

Vical

Virginia Commonwealth University

Vita-Salute University of Milano. Italy

Wake Forest University

Washington University in St. Louis

Xanthus Pharmaceuticals, Inc.

Xiamen University

Yale University

Yeshiva University

Zhengzhou University

ZNA Antwerpen

Organization Involved with Phase 1 Indications (132)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.